Nuplazid More Effective in Reducing Severe Psychosis in Alzheimer’s, Trial Shows

Nuplazid More Effective in Reducing Severe Psychosis in Alzheimer’s, Trial Shows
Nuplazid (pimavanserin) is more effective in reducing severe psychotic symptoms — particularly hallucinations and delusions — in Alzheimer’s disease patients than in those with milder symptoms, according to additional Phase 2 clinical trial results. The study, “Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms,” was published in The Journal of Prevention of Alzheimer's Disease. Patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease-associated dementia, and dementia with Lewy bodies, can develop dementia-related psychosis. Psychotic symptoms, including delusions and visual hallucinations, are estimated to occur in 25-50% of people with Alzheimer’s disease, and have been associated with faster cognitive and functional decline. Currently, there is no approved treatment for dementia-related psychosis, and off-label antipsychotic medications currently used to treat Alzheimer’s patients have been associated with a decline in cognition and with serious side effects. Nuplazid, developed by Acadia Pharmaceuticals, is the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease
Subscribe or to access all post and page content.

4 comments

Leave a Comment

Your email address will not be published. Required fields are marked *